Acute Osteomyelitis in Children

Heikki Peltola, M.D., and Markus Pääkkönen, M.D.

Bacteria may reach bone through direct inoculation from traumatic wounds, by spreading from adjacent tissue affected by cellulitis or septic arthritis, or through hematogenous seeding. In children, an acute bone infection is most often hematogenous in origin. In high-income countries, acute osteomyelitis occurs in about 8 of 100,000 children per year, but it is considerably more common in low-income countries. Boys are affected twice as often as girls. Unless acute osteomyelitis is diagnosed promptly and treated appropriately, it can be a devastating or even fatal disease with a high rate of sequelae, especially in resource-poor countries where patients present with advanced disease and survivors often have complications that are serious and long-lasting.

Staphylococcus aureus is by far the most common causative agent in osteomyelitis, followed by the respiratory pathogens Streptococcus pyogenes and S. pneumoniae. For unknown reasons, Haemophilus influenzae type b is more likely to affect joints than bones. Salmonella species are a common cause of osteomyelitis in developing countries and among patients with sickle cell disease. Infections due to Kingella kingae are increasing and are most common in children younger than 4 years of age.

Common Manifestations

When osteomyelitis is diagnosed, it is classified as acute if the duration of the illness has been less than 2 weeks, subacute for a duration of 2 weeks to 3 months, and chronic for a longer duration. Since any bone can be affected, patients can present with a wide variety of symptoms and signs. Multifocal osteomyelitis may occur at any age but occurs most frequently in neonates.

Classic clinical manifestations in children are limping or an inability to walk, fever and focal tenderness, and sometimes visible redness and swelling around a long bone, more often in a leg than in an arm (Fig. 1). Often the patient’s condition has deteriorated in the days preceding clinical presentation. Calcaneal osteomyelitis may proceed insidiously and lead to a delay in seeking treatment. Spinal osteomyelitis is characteristically manifested as back pain, whereas pain on a digital rectal examination suggests sacral osteomyelitis. Acute osteomyelitis should be considered in any patient who presents with a fever of unknown origin. Acute cases occur in all age groups, with a small peak in incidence among prepubertal boys, presumably because of strenuous physical activity and microtrauma. Children with methicillin-resistant S. aureus (MRSA) osteomyelitis have a high temperature, tachycardia, and a painful limp more often than those with methicillin-susceptible S. aureus (MSSA).

Diagnosis

The approach to the diagnosis of osteomyelitis in children is shown in Figure 2. If physical examination suggests bone involvement, further tests are performed.
Serum C-reactive protein (CRP) and procalcitonin levels are sensitive as diagnostic tests and useful in follow-up, but measurements of procalcitonin are more expensive and rarely outperform those of CRP, which are easily determined from a whole-blood finger-prick sample. Results of CRP testing are available within 10 minutes. Declining levels of CRP usually suggest a favorable response to treatment, even if the fever continues. Since the erythrocyte sedimentation rate increases rapidly but decreases significantly more slowly than the CRP level, it is less useful in monitoring the course of the illness. As compared with other types of osteomyelitis, osteomyelitis due to MRSA causes greater elevations in the CRP level, erythrocyte sedimentation rate, and white-cell count.

The “rat bite” in bone that is often seen in osteomyelitis becomes visible on plain radiography 2 to 3 weeks after the onset of symptoms and signs. A normal radiograph on admission to the hospital by no means rules out acute osteomyelitis, but it can be helpful in ruling out a fracture or detecting Ewing’s sarcoma or another type of malignant condition. In resource-poor countries, plain radiography is of great value, since no other imaging methods may be available.

Scintigraphy is sensitive and useful, especially if a long bone is affected or symptoms are not precisely localized. Although computed tomography (CT) is useful, it is cumbersome and entails extensive radiation exposure. Magnetic resonance imaging (MRI) is often considered the best imaging method, especially in difficult-to-diagnose cases. CT and MRI are costly, are not always available, and require anesthesia in young children. Ultrasonography is of minor importance, but visible fluid in an adjacent joint suggests septic arthritis.

Determining the causative organism is pivotal. Osteomyelitis can be diagnosed by means of imaging, but it is essential, whenever possible, to obtain a sample for the antibiogram that may disclose problematic agents such as MRSA. Representative samples can be obtained percutaneously or through a small incision by drilling. Blood cultures should be performed routinely, even though they identify the causative agent in only 40% of the cases. The yield of K. kingae can be increased with the use of special culture methods or polymerase-chain-reaction assays. K. kingae should be actively searched for, since it is difficult to isolate and appears to be more common among young children than previously thought.

**Management**

**Antibiotic Treatment**

Treatment of acute osteomyelitis is almost always instituted empirically before the causative agent and its resistance pattern are known. The most relevant antibiotics are listed in Table 1, and they must have an acceptable side-effect profile when administered orally because the doses are unusually large. Absorption and penetration into the bony structure should be satisfactory, and time-dependent antibiotics with a short circulating half-life are likely to require frequent dosing. Clindamycin and first-generation cephalosporins fulfill these requirements. Their efficacy as
Symptoms suggestive of acute osteomyelitis

Serum CRP, ESR, blood culture, and plain radiograph

Elevated CRP or ESR, or abnormal radiograph?

No

High suspicion of osteomyelitis

Observation, repeat CRP and ESR next day

Yes

MRI, bone scan, CT, bone biopsy, or all

Elevated CRP or ESR?

No

Repeat examinations Consider other diagnosis or discharge

Yes

MRI, bone scan, or CT suggestive of osteomyelitis?

No

Positive cultures from blood or bone?

No

Elevated CRP or ESR, or abnormal radiograph?

Yes

Elevated CRP or ESR?

No

Observation, repeat CRP and ESR next day

Yes

Positive cultures from blood or bone?

Treatment tailored to individual patient

Intravenous antibiotic

Neonate or immunodeficient patient

Antibiotic-resistant or atypical agent?

Yes

Check suitability of antibiotic, switch if needed

No

Abscess or complicated disease?

Yes

Evaluate need for surgery

No

Clinical improvement and decrease in CRP in 2–4 days?

No

Prolonged intravenous antibiotic Consider repeat imaging to rule out complications

Yes

MRSA?

No

Same high-dose antibiotic orally

Yes

Switch to oral antibiotic treatment if signs of clinical improvement and decrease in CRP

No

DISPONIBLE ANTIBIÓTIC

Discontinue antibiotic Total antibiotic treatment, approximately 3 wk

Yes

CRP normalized by day 20?

No

Extended oral antibiotic treatment Discontinue after most signs show clinical improvement and CRP normalized

No

Intravenous antibiotic treatment tailored to individual patient Total antibiotic treatment, usually 4–6 wk

No

Clinical improvement and decrease in CRP in 2–4 days?

Yes

CRP normalized by day 20?
Monotherapy for osteomyelitis has been documented, and large doses usually have an acceptable side-effect profile. Clindamycin very rarely causes diarrhea in children, but rash sometimes develops.

Treatment with antistaphylococcal penicillins has also been shown to be effective and safe, albeit in noncomparative or small prospective trials. Most MRSA strains remain susceptible to clindamycin, but it (as well as vancomycin) should not be used against K. kingae. Beta-lactams are the drugs of choice for cases of osteomyelitis due to K. kingae, as well as for those due to S. pyogenes or S. pneumoniae. The rare cases caused by H. influenzae type b respond to ampicillin or amoxicillin, if the strain is beta-lactamase-negative, or to a second- or third-generation cephalosporin, if the strain is beta-lactamase-positive. This agent should be considered especially in children younger than 4 years of age who have not been vaccinated against H. influenzae type b and who present with osteomyelitis and septic arthritis. For patients in unstable condition, and in areas where resistance to clindamycin is widespread, vancomycin should be chosen as a first-line agent, whereas the more costly linezolid should be reserved for patients who do not have a response to vancomycin. The adequacy of bone penetration is a concern when vancomycin is used and measurement of trough levels is warranted to guarantee sufficient dosing. A small retrospective survey yielded encouraging results with “old-fashioned” trimethoprim–sulfamethoxazole for osteomyelitis due to MRSA, but in the absence of data from larger trials, the use of this inexpensive and in many respects favorable agent remains controversial. Osteomyelitis due to salmonella warrants a third-generation cephalosporin, such as cefotaxime or ceftriaxone, or a fluoroquinolone. If these agents are not affordable, an older agent, chloramphenicol — which is currently not easy to obtain in developed countries — is a possibility, depending on the antibiogram profile. Its potential bone marrow effects are usually deemed to be outweighed by its benefits.

Patients with osteomyelitis may require other medications. At the attending clinician’s discretion, nonsteroidal antiinflammatory drugs (NSAIDs) can be used to lower the patient’s temperature and to relieve any harsh symptoms such as pain or fever. Data are lacking to support the use of glucocorticoids in acute osteomyelitis, but anticoagulants may be needed in cases that are complicated by deep-vein thrombosis, septic pulmonary emboli, or both; these conditions are characteristic of osteomyelitis due to MRSA.

**Switch from Intravenous to Oral Medication**

Traditionally, a child with osteomyelitis received intravenous medication for weeks, with a switch to oral medication when recovery was almost complete. This was understandable, since osteomyelitis killed many children or left them crippled. Antimicrobial agents revolutionized treatment, although few clinicians realize that the first sulfonamide regimens in the late 1930s were mostly oral and lasted for only a few days. Long intravenous courses were gradually adopted, and it took decades to relearn that switching to oral administration at an earlier point is not harmful. The pressing question continues to be how soon the switch can safely be achieved.

Three trials showed no change in outcomes when the intravenous phase was shorter than a week. A review from the United Kingdom concluded that short-term parenteral medication is acceptable in uncomplicated cases of osteomyelitis. In our prospective series involving 131 immunocompetent children who were older than 3 months of age, to our knowledge the largest study as of this writing, intravenous treatment was administered for only 2 to 4 days, followed by oral administration. There were no recrudescences, but no cases of MRSA were encountered. In countries such as the United States, where MRSA is a common pathogen, a more conservative approach is probably well founded while we await sufficiently powered prospective clinical trials to assess this important issue.
Table 1. Antibiotic Treatment for Acute Osteomyelitis in Children.ª

<table>
<thead>
<tr>
<th>Antibiotic</th>
<th>Dose†‡§</th>
<th>Maximal Daily Dose¶</th>
<th>Bone Penetration∥</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Empirical treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>First-generation cephalosporin, if prevalence of MSSA in community &gt;90%¶§</td>
<td>≥150 administered in 4 equal doses¶¶</td>
<td>2–4 g</td>
<td>6–7</td>
<td>Dose: Peltola et al., 9 Peltola et al. 20; extent of bone penetration: Tetzlaff et al. 21</td>
</tr>
<tr>
<td>Antistaphylococcal penicillin (cloxacillin, flucloxacillin, dicloxacillin, nafcillin, or oxacillin), if prevalence of MSSA in community &gt;90%¶§</td>
<td>≥200 administered in 4 equal doses¶¶</td>
<td>8–12 g</td>
<td>15–17</td>
<td>Dose: Jagodziński et al. 8; extent of bone penetration: Tetzlaff et al. 21</td>
</tr>
<tr>
<td>Clindamycin, if prevalence of MRSA in community ≥10% and prevalence of clindamycin-resistant S. aureus &lt;10%¶§</td>
<td>≥40 administered in 4 equal doses¶¶</td>
<td>Approximately 3 g</td>
<td>65–78</td>
<td>Prevalence of microorganisms: Liu et al. 14; dose: Peltola et al., 9 Liu et al., 14 Peltola et al. 20; extent of bone penetration: Feigin et al. 22</td>
</tr>
<tr>
<td>Vancomycin, if prevalence of MRSA in community ≥10% and prevalence of clindamycin-resistant S. aureus ≥10%¶§</td>
<td>≤40 administered in 4 equal doses¶¶</td>
<td>Dosing adjusted according to trough level, with a target of 15 to 20 µg per milliliter</td>
<td>5–67</td>
<td>Prevalence of microorganisms: Liu et al. 14; dose: Liu et al. 14; extent of bone penetration: Landersdorfer et al. 23</td>
</tr>
<tr>
<td>Linezolid, if no response to vancomycin¶§</td>
<td>30 administered in 3 equal doses¶¶</td>
<td>1.2 g for no more than 28 days</td>
<td>40–51</td>
<td>Dose: Kaplan et al., 24 Chen et al. 25; extent of bone penetration: Landersdorfer et al. 23</td>
</tr>
<tr>
<td>Alternatives for specific agents</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ampicillin or amoxicillin for group A beta-hemolytic streptococcus, Haemophilus influenzae type b (beta-lactamase-negative strains), and S. pneumoniae</td>
<td>150–200 administered in 4 equal doses¶¶</td>
<td>Approximately 8–12 g</td>
<td>3–31</td>
<td>Dose: Peltola et al.; extent of bone penetration: Landersdorfer et al. 23</td>
</tr>
<tr>
<td>Chloramphenicol, if safer agents not available or affordable</td>
<td>75 administered in 3 equal doses¶¶</td>
<td>2–4 g</td>
<td>39</td>
<td>Dose: Krogstad; extent of bone penetration: Summersgill et al. 26</td>
</tr>
</tbody>
</table>

ª When relevant, the same dose may be used parenterally and orally. MRSA denotes methicillin-resistant Staphylococcus aureus, and MSSA methicillin-susceptible S. aureus.
† The maximal daily dose is not always well defined, but the maximal adult dose should not be exceeded.
‡ Bone penetration is the ratio of the bone concentration to the serum concentration.
§ Data on antistaphylococcal penicillins, first-generation cephalosporins, and clindamycin21,22 are from in vivo studies involving children; the remaining data were derived from studies involving adults or from experimental models.
¶ Chloramphenicol at a dose of 100 mg per kilogram of body weight per day in four equal doses is generally used in bacterial meningitis.

DURATION OF TREATMENT AND DIFFICULT-TO-TREAT PATHOGENS

In one study in 1960, two factors — a delay in initiating treatment and antibiotic courses of less than 3 weeks’ duration — were deemed to be risk factors for relapse,41 although other retrospective studies showed no advantage with courses that were prolonged for more than approximately 21 days.4,5 In a British study, cloxacillin was administered for “an arbitrary period of five weeks,”28 and this approach became almost dogma for four decades.6,14,42 In our prospective randomized trial, a 20-day regimen of high-dose clindamycin or a first-generation cephalosporin (doses are listed in Table 1) performed as well as a 30-day regimen for osteomyelitis caused by MSSA, streptococci, or pneumococci. 9,20 Shortened regimens of primarily oral antibiotics appear to simplify the entire treatment process in terms of the required hospital stay, the antibiotics used, and the risk of adverse events; in addition, the risk of bacterial resistance is reduced. Furthermore, with very few exceptions, oral antibiotics are considerably cheaper than parenteral formulations, and oral administration on an outpatient basis also reduces the cost of treatment.
Current clinical-practice guidelines of the Infectious Diseases Society of America recommend individualized therapy and typically a minimum of 4 to 6 weeks of medication for children with acute osteomyelitis due to MRSA. Since data on short-term treatment for cases due to MRSA or the virulent Panton–Valentine leukocidin gene-expressing S. aureus are lacking, this recommendation is justified. It may also apply to patients who present with advanced disease and those in areas where osteomyelitis due to salmonella is common. Pathologic fractures are associated with a type of MRSA that is characterized by a single pulsed-field pattern (strain USA300-0114), but even a fracture does not necessarily warrant surgical intervention. As compared with MSSA, MRSA is more frequently associated with deep-vein thrombosis, septic pulmonary emboli, or both. Whereas resistance to methicillin is associated with an increased risk of complications in staphylococcal disease, pneumococcal resistance to penicillin has not been associated with an increased risk of complications in pneumococcal osteoarticular disease.

There are some other caveats in relation to shorter treatments as well. Although data are lacking on the use of shorter treatments in neonates, immunocompromised or malnourished patients, and patients with sickle cell disease, these patients are likely to need a longer course of medication. When acute osteomyelitis is complicated by septic arthritis, the disease is chronic, and the CRP level normalizes slowly, a longer course probably also makes sense. Figure 2 summarizes the treatment of acute osteomyelitis.

**CASE REPORT**

Fever, focal redness (Fig. 3A), and pain in the left biceps region developed in an 8-year-old boy who had not had prior trauma. A radiograph obtained 2 days later was normal (July 10 in Fig. 3B), the leukocyte count was 10,000 per cubic millimeter, and the serum CRP level was clearly increased, at 106 mg per liter (normal level, <20). The child was hospitalized. Three days later, the leukocyte count was only 4100 per cubic millimeter, whereas the CRP level had increased to 384 mg per liter, and the erythrocyte sedimentation rate was 66 mm per hour (normal level, <20). MRI showed massive edema around the proximal humerus. A specimen for bacteriology was drilled from the bone, and a blood culture was obtained; acute osteomyelitis was diagnosed. Intravenous clindamycin was administered, with cefuroxime for concomitant pneumonia. The child's condition deteriorated for 2 days, and then he began to recover. MSSA grew from the bone and blood cultures. Treatment with clindamycin was switched to oral administration on day 2, and cefuroxime was discontinued on day 7. The boy was discharged on day 11, when the CRP level was 113 mg per liter and the erythrocyte sedimentation rate was 117 mm per hour. On day 20, recovery was well advanced, and because the CRP level had normalized, clindamycin was discontinued. The patient was afebrile, but the erythrocyte sedimentation rate was still elevated, at 100 mm per hour.

At follow-up 1 month later, the boy's parents reported that he was doing well, except that climbing a ladder caused pain in the upper arm. A plain radiograph (Sept. 2 in Fig. 3B) revealed a patho-
logic fracture in addition to callus formation and other signs of healing. Since the bone was stable and the CRP level and erythrocyte sedimentation rate had normalized, antimicrobial treatment was not reinitiated. The recovery was uneventful. Two years later, the boy was well and the fracture had healed, with no bone or joint infections. Seven years after the disease, the patient remained asymptomatic. Figure 3B shows the radiographic findings during and after this potentially life-threatening, septicemic S. aureus infection.

Clinicians tend to prolong or reinstitute antibiotic therapy and often recommend surgery in patients with a pathologic fracture.44,47 One should, however, distinguish active infection, in which bacteria are still alive, from inflammation, a much lengthier process. Spontaneous healing was well under way 1 month after discharge, and no fistula had developed. The normalized CRP level and erythrocyte sedimentation rate virtually ruled out ongoing active infection.16 Even fever, which is a less specific warning sign than CRP in osteoarticular infections, was absent, and the child’s general condition was good.18 Furthermore, a radiograph showed good callus formation — another favorable sign. Ultimately, we saw no indication for reinstituting antibiotics; pain relief and watchful waiting sufficed at this stage of recovery.

**Response to Treatment and Outcomes**

Unlike cases of acute osteomyelitis in developing countries, those in developed countries are rarely fatal. In a national epidemiologic study in France involving more than 1000 children with osteomyelitis, only 1 child died.3 Hospital admission that is delayed for 5 days or more is a probable risk factor for slow recovery and a poor outcome.9,41 Usually, active infection is eliminated rather easily with well-targeted antibiotics, whereas the inflammatory process, which ultimately heals the bone, may persist for months. Antibiotics play no role at this stage, but NSAIDs may be used to mitigate symptoms. Follow-up for a year or more is justified, since sequelae such as growth disturbance may emerge slowly. Our own study included 131 children with culture-confirmed acute osteomyelitis; mild sequelae developed in only 2 children.9 Less favorable outcomes may occur, since sequelae rates vary regionally and depend on many factors such as antibiotic resistance, economic conditions, and access to health care.6-9,35,36,43,44 Overall, however, the past few years have seen great strides in simplifying the treatment of acute osteomyelitis in children.

Dr. Peltola reports receiving consulting fees from the Serum Institute of India and lecture fees from Novartis. Dr. Pääkkönen reports receiving travel support from Synthes. No other potential conflict of interest relevant to this article was reported.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

We thank Pentti Kallio, M.D., for orthopedic consultation regarding the patient described in the vignette; Richard Burton for checking the linguistic accuracy; and Juho Ajanki for assistance with an earlier draft of Figure 1.
OSTEOMYELITIS IN CHILDREN

REFERENCES


34. Bocchini CE, Hulten KG, Mason EO

The New England Journal of Medicine
Downloaded from nejm.org by Sydney King on October 22, 2019. For personal use only. No other uses without permission. Copyright © 2014 Massachusetts Medical Society. All rights reserved.


Copyright © 2014 Massachusetts Medical Society.